All HFA B-ALL patients had high-risk molecular abnormalities, including BCR-ABL (3/8, 37.5%; one of the patients had T315I mutation), ph-like (Ikaros 6) (1/8, 12.5%), E2A/PBX1 fusion gene (1/8, 12.5%) and complex karyotypes (4/8, 50.0%). This evidence concerns the gene PBX1 and acute lymphoblastic leukemia.